Guideline Adaptation: An Appealing Alternative to De Novo Guideline Development

  1. Valerie A. Palda, MD, MSc;
  2. Ian D. Graham, PhD;
  3. Dave Davis, MD;
  4. Jako Burgers, MD, PhD;
  5. Melissa Brouwers, PhD;
  6. Françoise Cluzeau, PhD; and
  7. On behalf of the AGREE research trust
  1. From the University of Toronto, Toronto, Ontario M5B 1W8, Canada.

    TO THE EDITOR:

    We read with interest the ACP guidelines (1) on glycemic control in type 2 diabetes mellitus. The use of the AGREE instrument to compare the methodological rigor of various guidelines is a meaningful step forward. To our knowledge, it is used regularly only by a few groups, such as the Guidelines Advisory Committee in Ontario (http://www.gacguidelines.ca), and more widely in Europe by the Belgian Centre for Evidence-Based Medicine (http://www.cebam.be) and others (http://www.agreetrust.org/links.htm). Using well-developed guidelines as a basis for forming …

    [Full Text of this Article]

    Summary for Patients

    • Clinical Guidelines:Glycemic Control and Type 2 Diabetes Mellitus: The Optimal Hemoglobin A1c Targets. A Guidance Statement from the American College of Physicians
      • Amir Qaseem,
      • Sandeep Vijan,
      • Vincenza Snow,
      • J. Thomas Cross,
      • Kevin B. Weiss,
      • Douglas K. Owens,
      • and for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians*
      Ann Intern Med September 18, 2007 147:417-422
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 1, 2008 vol. 148 no. 7 564
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues